Cargando…

Loss of asthma control after cessation of omalizumab treatment: real life data

INTRODUCTION: Many clinical and observational studies have demonstrated effectiveness of omalizumab (OMA) in the treatment of severe asthma, but the optimal duration of the therapy remains unknown. AIM: The article presents the authors’ clinical experience on OMA cessation in routine practice. MATER...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kupryś-Lipińska, Izabela, Kuna, Piotr
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2014
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3952048/ https://www.ncbi.nlm.nih.gov/pubmed/24683390 http://dx.doi.org/10.5114/pdia.2014.40553

Ejemplares similares

Good outcomes of pregnancy in two cases of women treated with omalizumab due to the severe asthma
por: Kuprys-Lipinska, Izabela, et al.
Publicado: (2013)

Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience
por: Kupryś-Lipińska, Izabela, et al.
Publicado: (2016)

Omalizumab in pregnant women treated due to severe asthma: two case reports of good outcomes of pregnancies
por: Kupryś-Lipińska, Izabela, et al.
Publicado: (2014)

Omalizumab therapy in a patient with severe asthma and co-existing chronic obstructive pulmonary disease
por: Kupryś-Lipińska, Izabela, et al.
Publicado: (2018)

Effectiveness of omalizumab in a patient with a life-threatening episode of bronchospasm and larynx angioedema after exposure to house dust
por: Kupryś-Lipińska, Izabela, et al.
Publicado: (2014)

Effectiveness of omalizumab in an asthmatic patient with severe airway and blood eosinophilia
por: Kupryś-Lipińska, Izabela, et al.
Publicado: (2015)

New approach to intermittent and mild asthma therapy: evolution or revolution in the GINA guidelines?
por: Kuprys-Lipinska, Izabela, et al.
Publicado: (2020)

Polish Society of Allergology statement on the diagnosis and treatment of severe, difficult-to-control bronchial asthma
por: Kupczyk, Maciej, et al.
Publicado: (2019)

Prevalence, risk factors and underdiagnosis of asthma in the general population aged over 60 years
por: Kuprys-Lipinska, Izabela, et al.
Publicado: (2019)

287 Nasal Nitric Oxide Levels after Lysine Aspirin Nasal Challenge in Subjects with Aspirin Induced Asthma
por: Tworek, Damian, et al.
Publicado: (2012)

The position paper of the Polish Society of Allergology on climate changes, natural disasters and allergy and asthma
por: Pałczyński, Cezary, et al.
Publicado: (2018)

Effectiveness and adverse events of plasmapheresis and immunoglobulin G infusion in patient with resistant chronic urticaria and angioedema - a case report
por: Kuprys-Lipinska, Izabela, et al.
Publicado: (2015)

Omalizumab in an allergology clinic: real life experience and future developments
por: Kupczyk, Maciej, et al.
Publicado: (2014)

Omalizumab in Children with Severe Allergic Asthma: The Italian Real-Life Experience
por: Licari, Amelia, et al.
Publicado: (2017)

The Step Further to Understand the Role of Cytosolic Phospholipase A(2) Alpha and Group X Secretory Phospholipase A(2) in Allergic Inflammation: Pilot Study
por: Pniewska, Ewa, et al.
Publicado: (2014)

Omalizumab treatment in brittle asthma
por: Skiepko, Roman, et al.
Publicado: (2014)

Real-Life Benefit of Omalizumab in Improving Control of Bronchial Asthma During COVID-19 Pandemic
por: Leru, Polliana Mihaela, et al.
Publicado: (2021)

Omalizumab is effective in nasal polyposis with or without asthma, a real-life study
por: Tat, Tuğba Songül
Publicado: (2022)

Real-life Effectiveness of Omalizumab in Patients with Severe Allergic Asthma: RELIEF Study
por: Al Ahmad, Mona, et al.
Publicado: (2022)

Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
por: Torres-Duque, Carlos A., et al.
Publicado: (2022)

Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study
por: Solidoro, Paolo, et al.
Publicado: (2019)

Expression of Transcript Variants of PTGS1 and PTGS2 Genes among Patients with Chronic Rhinosinusitis with Nasal Polyps
por: Pietruszewska, Wioletta, et al.
Publicado: (2021)

Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study
por: Canonica, Giorgio Walter, et al.
Publicado: (2018)

Follow-up of asthma control and quality of life after discontinuation of omalizumab in severe asthmatic patients
por: Nayci, Sibel, et al.
Publicado: (2015)

Severe asthma and the omalizumab option
por: Miller, Christopher WT, et al.
Publicado: (2008)

Real-life Efficacy of Omalizumab After 9 Years of Follow-up
por: Menzella, Francesco, et al.
Publicado: (2017)

The whole - genome expression analysis of peripheral blood mononuclear cells from aspirin sensitive asthmatics versus aspirin tolerant patients and healthy donors after in vitro aspirin challenge
por: Wieczfinska, Joanna, et al.
Publicado: (2015)

Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness
por: Pelaia, Corrado, et al.
Publicado: (2018)

Expression of cPLA(2)γ mRNA and protein differs the response of PBMC from severe and non-severe asthmatics to bacterial lipopolysaccharide and house dust mite allergen
por: Pniewska-Dawidczyk, Ewa, et al.
Publicado: (2021)

Omalizumab for severe allergic asthma: a life changing drug?
por: Mesonjesi, Eris, et al.
Publicado: (2015)

Omalizumab for Severe Asthma: Beyond Allergic Asthma
por: Loureiro, C. C., et al.
Publicado: (2018)

Omalizumab and IgE in the Control of Severe Allergic Asthma
por: Gon, Yasuhiro, et al.
Publicado: (2022)

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
por: Snelder, S. M., et al.
Publicado: (2017)

Omalizumab: the evidence for its place in the treatment of allergic asthma
por: McNicholl, Diarmuid M., et al.
Publicado: (2008)

Omalizumab: clinical use for the treatment of an adolescent with difficult asthma
por: De Castro, Giovanna, et al.
Publicado: (2013)

Appropriate selection for omalizumab treatment in patients with severe asthma?
por: Nygaard, Leo, et al.
Publicado: (2017)

Quality of life in asthmatic children and their caregivers after two-year treatment with omalizumab, a real-life study
por: Sztafińska, Anna, et al.
Publicado: (2017)

Therapeutic Effect of Omalizumab in Severe Asthma: A Real-World Study in Korea
por: Lee, Ji-Ho, et al.
Publicado: (2018)

Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience
por: Caminati, M., et al.
Publicado: (2016)

Real-life effectiveness of omalizumab in difficult-to-treat versus severe asthma: a national cohort study in Belgium
por: Verhamme, Katia M.C., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_j4eislpu2irhth9evn4uqsrtgp